|Mr. David R. Epstein||Exec. Chairman||495k||N/A||1962|
|Dr. Pablo J. Cagnoni Ph.D., M.D.||CEO, Pres & Director||1.01M||N/A||1963|
|Mr. Laurence A. Turka M.D.||Chief Scientific Officer||704.94k||N/A||1958|
|Dr. Christina M. Coughlin B.S., M.D., Ph.D.||Chief Medical Officer||700.97k||N/A||1970|
|Mr. Jose I. Carmona||CFO, Principal Accounting Officer & Treasurer||N/A||N/A||1972|
|Ms. Joanne M. Protano||Sr. VP of Fin. & Operations||N/A||N/A||1969|
|Mr. Spencer Fisk||Sr. VP of Manufacturing & CTO||N/A||N/A||N/A|
|Ms. Lori Melancon||Chief Corp. Affairs Officer||N/A||N/A||N/A|
|Ms. Elhan Webb C.F.A.||VP of Investor Relations||N/A||N/A||N/A|
|Ms. Maiken Keson-Brookes||Chief Legal Officer & Corp. Sec.||N/A||N/A||1973|
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Rubius Therapeutics, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 8.